A- A A+

Yee Chao (趙毅)

  • 2875-7270
Yee Chao(趙毅)

簡介

學歷
  1. 國立陽明大學 臨床醫學研究所 博士
  2. 高雄醫學大學 醫學系 醫學士
經歷 現職:
  1. 2016- 迄今 臺北榮民總醫院 腫瘤醫學部 部主任
  2. - 迄今 國立陽明大學 醫學院 教授
經歷:
  1. 2014- 2016 臺北榮民總醫院 勞工安全衛生室 室主任
  2. 1998- 2014 臺北榮民總醫院 癌病中心 藥物放射治療科 科主任
  3. 1990- 1998 臺北榮民總醫院 內科部 胃腸科 主治醫師
  4. - 臺北榮民總醫院 內科部 胃腸科 臨床研究員
醫療專長
  1. 胃癌,肝癌,胰臟癌,消化系腫瘤,大腸癌,食道癌
證照
  1. 台灣醫師執照、內科專科醫師、台灣臨床腫瘤醫學會臨床專科醫師、消化系內科專科醫師、消化系內視鏡專科醫師
語言專長
  1. 英文

著作

PubMed


  1. Chao Y*, Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY.  The Combination of Transcatheter Arterial Chemoembolization and Sorafenib is Well Tolerated and Effective in Asian Patients with Hepatocellular Carcinoma: Final Results of the START Trial. Int J Cancer 2015 Mar; 136(6): 1458-67. (IF: 5.531; Oncology 29/213)

  2. Chou WC, Lin PH, Yeh YC, Shyr YM, Fang WL, Wang SE, Liu CY, Chang PM, Chen MH, Hung YP, Li CP, Chao Y*, Chen MH*.  Genes Involved in Angiogenesis and mTOR Pathways Are Frequently Mutated in Asian Patients with Pancreatic Neuroendocrine Tumors. Int J Biol Sci 2016 Nov; 12(12): 1523-32. (IF: 3.982; Biochemistry & Molecular Biology 78/289)

  3. Hung YP, Liu CJ, Hu YW, Chen MH, Li CP, Yeh CM, Chiou TJ, Chen TJ, Yang MH, Chao Y*.  Secondary Primary Malignancy Risk in Patients with Ovarian Cancer in Taiwan: A Nation-Wide Population-Based Study. Medicine (Baltimore) 2015 Sep; 94(38): e1626. (IF: 2.133; Medicine, General & Internal 40/155)

  4. Fang WL, Hung YP, Liu CJ*, Lan YT, Huang KH, Chen MH, Lo SS, Shyr YM, Wu CW, Yang MH, Chen TJ, Chao Y*.  Incidence of and Risk Factors for Tuberculosis (TB) in Gastric Cancer Patients in an Area Endemic for TB: A Nation-Wide Population-Based Matched Cohort Study. Medicine (Baltimore) 2015 Nov; 94(47): e2163. (IF: 2.133; Medicine, General & Internal 40/155)

  5. Tseng CL, Lai WJ, Huang CJ, Huang YH, Su CW, Lee IC, Tseng HS, Li CP, Lee RC, Lin HC, Chao Y*.  The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment: A Cohort Study in Taiwan. Medicine (Baltimore) 2015 Nov; 94(47): e1659. (IF: 2.133; Medicine, General & Internal 40/155)

  6. Chen MH, Lin J, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP*, Chao Y*.  A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed By Docetaxel Plus Capecitabine in Patients with Unresectable Gastric Adenocarcinoma: the TCOG 3211 Clinical Trial. Medicine (Baltimore) 2016 Jan; 95(3): e2565. (IF: 2.133; Medicine, General & Internal 40/155)

  7. Lee TY, Lin CC, Chen CY, Wang TE, Lo GH, Chang CS, Chao Y*.  Combination of Transcatheter Arterial Chemoembolization and Interrupted Dosing Sorafenib Improves Patient Survival in Early-Intermediate Stage Hepatocellular Carcinoma: A Post Hoc Analysis of the START Trial. Medicine (Baltimore) 2017 Sep; 96(37): e7655. (IF: 1.803; Medicine, General & Internal 58/154)

  8. Hung YP, Chen MH, Lin JS, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP, Chao Y*.  The Clinical Impact of the Novel Tumor Marker DR-70 in Unresectable Gastric Cancer Patients. J Chin Med Assoc 2018 Apr. [Epub ahead of print] (IF: 1.252; Medicine, General & Internal 82/154)

  9. Chen MH, Kuo YJ, Yeh YC, Lin YC, Tzeng CH, Liu CY, Chang PM, Chen MH, Jeng YM, Chao Y*.  High Neuroendocrine Component is a Factor for Poor Prognosis in Gastrointestinal High-Grade Malignant Mixed Adenoneuroendocrine Neoplasms. J Chin Med Assoc 2015 Aug; 78(8): 454-9. Epub 2015 May. (IF: 1.013; Medicine, General & Internal 88/155)


  1. Kang YK, Boku N*, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT.  Nivolumab in Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2): a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet 2017 Dec; 390(10111): 2461-71. Epub 2017 Oct. (IF: 47.831; Medicine, General & Internal 2/155)

  2. Cutsem EV*, Bang YJ, Mansoor W, Petty RD, Chao Y, Cunningham D, Ferry DR, Smith NR, Frewer P, Ratnayake J, Stockman PK, Kilgour E, Landers D.  A Randomized, Open-Label Study of the Efficacy and Safety of AZD4547 Monotherapy versus Paclitaxel for the Treatment of Advanced Gastric Adenocarcinoma with FGFR2 Polysomy or Gene Amplification. Ann Oncol 2017 Jun; 28(6): 1316-24. (IF: 11.855; Oncology 10/217)

  3. Abou-Alfa G*, Qin S, Ryoo BY, Lu SN, Yen CJ, Feng YH, Lim HY, Izzo F, Colombo M, Sarker D, Bolondi L, Vaccaro G, Harris WP, Chen Z, Hubner RA, Meyer T, Sun W, Harding JJ, Hollywood EM, Ma J, Wan PJ, Ly M, Bomalaski J, Johnston A, Lin CC, Chao Y, Chen LT.  Phase III Randomized Study of Second Line ADI-PEG 20 Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma. Ann Oncol 2018 Apr. [Epub ahead of print] (IF: 11.855; Oncology 10/217)

  4. Cheng AL, Thongprasert S, Lim HY, Sukeepaisarnjaroen W, Yang TS, Wu CC, Chao Y, Chan SL, Kudo M, Ikeda M, Kang YK, Pan H, Numata K, Han G, Balsara B, Zhang Y, Rodriguez AM, Zhang Y, Wang Y, Poon RT.  Randomized, Open-Label Phase 2 Study Comparing Frontline Dovitinib VS Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Hepatology 2016 Sep; 64(3): 774-84. (IF: 11.711; Gastroenterology & Hepatology 4/79)

  5. Yau TC, Lencioni R, Sukeepaisarnjaroen W, Chao Y, Yen CJ, Lausoontornsiri W, Chen PJ, Sanpajit T, Camp A, Cox DS, Gagnon RC, Liu Y, Raffensperger KE, Kulkarni DA, Kallender H, Ottesen LH, Poon RT, Bottaro DP*.  A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2017 May; 23(10): 2405-13. Epub 2016 Nov. (IF: 9.619; Oncology 12/217)

  6. Chen SC, Chao Y, Yang MH*.  Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report. Am J Gastroenterol 2017 Apr; 112(4): 659-60. (IF: 9.566; Gastroenterology & Hepatology 6/79)

  7. Chen JS, Hsu C, Chiang NJ, Tsai CS, Tsou HH, Huang SF, Bai LY, Chang IC, Shiah HS, Ho CL, Yen CJ, Lee KD, Chiu CF, Rau KM, Yu MS, Yang Y, Hsieh RK, Chang JY, Shan YS, Chao Y, Chen LT.  A KRAS Mutation Status-Stratified Randomized Phase II Trial of Gemcitabine and Oxaliplatin Alone Or in Combination with Cetuximab in Advanced Biliary Tract Cancer. Ann Oncol 2015 May; 26(5): 943-9. Epub 2015 Jan. (IF: 9.269; Oncology 11/213)

  8. Yen CJ, Kim TY, Feng YH, Chao Y, Lin DY, Ryoo BY, Huang D CL, Schnell D, Hocke J, Loembé AB, Cheng AL*.  A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2018 Mar. [Epub ahead of print] (IF: 7.854; Oncology 18/217; Gastroenterology & Hepatology 7/79)

  9. Lee WP, Lan KH, Li CP, Chao Y, Lin HC, Lee SD.  Akt Phosphorylates Myc-Associated Zinc Finger Protein (MAZ), Releases P-MAZ From the P53 Promoter, and Activates P53 Transcription. Cancer Lett 2016 May; 375(1): 9-19. (IF: 5.992; Oncology 23/213)

  10. Wang JP, Kao FY, Wu CY, Hung YP, Chao Y, Chou YJ, Li CP.  Nucleos(t)ide Analogues Associated with a Reduced Risk of Hepatocellular Carcinoma in Hepatitis B Patients: A Population-Based Cohort Study. Cancer 2015 May; 121(9): 1446-55. (IF: 5.649; Oncology 26/213)

  11. Fang WL, Lan YT, Huang KH, Liu CA, Hung YP, Lin CH, Jhang FY, Chang SC*, Chen MH, Chao Y, Lin WC, Lo SS, Fen-Yau Li A, Wu CW, Chiou SH, Shyr YM*.  Clinical Significance of Circulating Plasma DNA in Gastric Cancer. Int J Cancer 2016 Jun; 138(12): 2974-83. (IF: 5.531; Oncology 29/213)

  12. Lee WP*, Lan KH, Li CP, Chao Y, Hou MC, Lin HC, Lee SD.  The Telomere-Binding Protein TRF2 is Required for Metronomic Therapeutic Effects of Gemcitabine and Capecitabine. Biochim Biophys Acta 2017 Apr; 1863(4): 917-28. Epub 2017 Jan. (IF: 5.476; Biophysics 9/72; Biochemistry & Molecular Biology 45/286)

  13. Chiang NJ, Hsu C, Chen JS, Tsou HH, Shen YY, Chao Y, Chen MH, Yeh TS, Shan YS, Huang SF, Chen LT*.  Expression Levels of ROS1/ALK/c-MET and Therapeutic Efficacy of Cetuximab Plus Chemotherapy in Advanced Biliary Tract Cancer. Sci Rep 2016 May; 6(): 25369. (IF: 5.228; Multidisciplinary Sciences 7/63)

  14. Lee WP, Lan KH, Li CP, Chao Y, Lin HC, Lee SD.  Oncogenic Circuit Constituted By Ser31-HBx and Akt Increases Risks of Chronic Hepatitis and Hepatocellular Carcinoma. Biochim Biophys Acta 2016 Apr; 1862(4): 837-49. Epub 2016 Jan. (IF: 5.158; Biophysics 10/72; Biochemistry & Molecular Biology 49/289)

  15. Wang JP, Wu CY, Yeh YC, Shyr YM, Wu YY, Kuo CY, Hung YP, Chen MH, Lee WP, Luo JC, Chao Y, Li CP.  Erlotinib is Effective in Pancreatic Cancer with Epidermal Growth Factor Receptor Mutations: A Randomized, Open-Label, Prospective Trial. Oncotarget 2015 Jul; 6(20): 18162-73. (IF: 5.008; Oncology 36/213; Cell Biology 43/187)

  16. Chen MH, Yen CC, Cheng CT, Wu RC, Huang SC, Yu CS, Chung YH, Liu CY, Chang PM, Chao Y, Chen MH, Chen YF, Chiang KC, Yeh TS, Chen TC, Huang CY, Yeh CN.  Identification of SPHK1 as a Therapeutic Target and Marker of Poor Prognosis in Cholangiocarcinoma. Oncotarget 2015 Sep; 6(27): 23594-608. (IF: 5.008; Oncology 36/213; Cell Biology 43/187)

  17. Fang WL, Huang KH, Lan YT, Lin CH, Chang SC*, Chen MH, Chao Y, Lin WC, Lo SS, Li AF, Wu CW, Chiou SH, Shyr YM*.  Mutations in PI3K/AKT Pathway Genes and Amplifications of PIK3CA Are Associated with Patterns of Recurrence in Gastric Cancers. Oncotarget 2016 Feb; 7(5): 6201-20. (IF: 5.008; Oncology 36/213; Cell Biology 43/187)

  18. Hsieh WY, Chen PH, Lin IY, Su CW*, Chao Y, Huo TI, Huang YH, Hou MC*, Lin HC, Wu JC.  The Impact of Esophagogastric Varices on the Prognosis of Patients with Hepatocellular Carcinoma. Sci Rep 2017 Feb; 7(): 42577. (IF: 4.259; Multidisciplinary Sciences 10/64)

  19. Lee PC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lee MH, Hou MC, Lee FY, Lin HC, Huang YH*.  Validation of the ALBI Grade-Based Integrated Model as a Predictor for Sorafenib-Failed Hepatocellular Carcinoma. Liver Int 2018 Feb; 38(2): 321-30. Epub 2017 Aug. (IF: 4.116; Gastroenterology & Hepatology 17/79)

  20. Lee PC, Yeh CM, Hu YW, Chen CC, Liu CJ*, Su CW*, Huo TI, Huang YH, Chao Y, Chen TJ, Lin HC, Wu JC.  Antiplatelet Therapy Is Associated with A Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. Ann Surg Oncol 2016 Dec; 23(Suppl 5): 874-83. (IF: 3.655; Surgery 16/200; Oncology 70/213)

  21. Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, Shimada Y, Topuzov E, Van Cutsem E, Tabernero J, Zalcberg J, Chau I, Cascinu S, Cheng R, Hsu Y, Emig M, Orlando M, Fuchs C*.  Age Does Not Influence Efficacy of Ramucirumab in Advanced Gastric Cancer: Subgroup Analyses of REGARD and RAINBOW. J Gastroenterol Hepatol 2018 Apr; 33(4): 814-24. Epub 2017 Sep. (IF: 3.452; Gastroenterology & Hepatology 27/79)

  22. Muro K, Oh SC, Shimada Y, Lee KW, Yen CJ, Chao Y, Cho JY, Cheng R, Carlesi R, Chandrawansa K, Orlando M, Ohtsu A.  Subgroup Analysis of East Asians in RAINBOW: A Phase 3 Trial of Ramucirumab Plus Paclitaxel for Advanced Gastric Cancer. J Gastroenterol Hepatol 2016 Mar; 31(3): 581-9. (IF: 3.322; Gastroenterology & Hepatology 25/79)

  23. Lan YT, Huang KH, Liu CA, Tai LC, Chen MH, Chao Y, Li AF, Chiou SH, Shyr YM, Wu CW, Fang WL.  A Nation-Wide Cancer Registry-Based Study of Adenosquamous Carcinoma in Taiwan. PLoS One 2015 Oct; 10(10): e0139748. (IF: 3.057; Multidisciplinary Sciences 11/63)

  24. Ye BW, Chou CK, Hsieh YC, Li CP, Chao Y, Hou MC, Lin HC, Lee KC*.  Metallic Stent Expansion Rate at Day One Predicts Stent Patency in Patients with Gastric Outlet Obstruction. Dig Dis Sci 2017 May; 62(5): 1286-94. Epub 2017 Mar. (IF: 2.875; Gastroenterology & Hepatology 39/79)

  25. Lee WP, Hou MC, Lan KH, Li CP, Chao Y, Lin HC, Lee SD.  Helicobacter Pylori-Induced Chronic Inflammation Causes Telomere Shortening of Gastric Mucosa By Promoting PARP-1-Mediated Non-Homologous End Joining of DNA. Arch Biochem Biophys 2016 Sep; 606(): 90-8. (IF: 2.807; Biophysics 28/72; Biochemistry & Molecular Biology 137/289)

  26. Fang WL*, Huang KH, Chen MH, Liu CA, Hung YP, Chao Y, Tai LC, Lo SS, Li AF, Wu CW, Shyr YM.  Comparative Study of the 7th and 8th AJCC Editions for Gastric Cancer Patients after Curative Surgery. PLoS One 2017 Nov; 12(11): e0187626. (IF: 2.806; Multidisciplinary Sciences 15/64)

  27. Lee IC, Chau GY, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Huang YH*.  Risk of Recurrence in Chronic Hepatitis B Patients Developing Hepatocellular Carcinoma with Antiviral Secondary Prevention Failure. PLoS One 2017 Nov; 12(11): e0188552. (IF: 2.806; Multidisciplinary Sciences 15/64)

  28. Huang KH, Lan YT, Chen MH, Chao Y, Lo SS, Li AF, Wu CW, Chiou SH, Yang MH, Shyr YM, Fang WL.  The Correlation Between RhoA Expression and Clinicopathological Characteristics in Gastric Cancer Patients after Curative Surgery. World J Surg 2015 Sep; 39(9): 2289-99. (IF: 2.523; Surgery 53/200)

  29. Lee IC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH.  Determinants of Survival after Sorafenib Failure in Patients with BCLC-C Hepatocellular Carcinoma in Real-World Practice. Medicine (Baltimore) 2015 Apr; 94(14): e688. (IF: 2.133; Medicine, General & Internal 40/155)

  30. Ye BW, Lee KC, Hsieh YC, Li CP, Chao Y, Hou MC, Lin HC.  Self-Expandable Metallic Stent Placement in Malignant Gastric Outlet Obstruction: A Comparison Between 2 Brands of Stents. Medicine (Baltimore) 2015 Jul; 94(29): e1208. (IF: 2.133; Medicine, General & Internal 40/155)

  31. Kao WY, Chao Y, Chang CC, Li CP, Su CW, Huo TI, Huang YH, Chang YJ, Lin HC, Wu JC.  Prognosis of Early-Stage Hepatocellular Carcinoma: the Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 Patients. Medicine (Baltimore) 2015 Oct; 94(43): e1929. (IF: 2.133; Medicine, General & Internal 40/155)

  32. Teng CJ, Huon LK, Hu YW, Yeh CM, Chao Y, Yang MH, Chen TJ, Hung YP, Liu CJ.  Secondary Primary Malignancy Risk in Patients with Cervical Cancer in Taiwan: A Nation-Wide Population-Based Study. Medicine (Baltimore) 2015 Oct; 94(43): e1803. (IF: 2.133; Medicine, General & Internal 40/155)

  33. Chen YY, Li AF, Huang KH, Lan YT, Chen MH, Chao Y, Lo SS, Wu CW, Shyr YM, Fang WL.  Adenosquamous Carcinoma of the Stomach and Review of the Literature. Pathol Oncol Res 2015 Jul; 21(3): 547-51. (IF: 1.940; Pathology 36/79; Oncology 157/213)

  34. Fang WL, Huang KH, Lan YT, Chen MH, Chao Y, Lo SS, Wu CW, Shyr YM, Li AF.  The Risk Factors of Lymph Node Metastasis in Early Gastric Cancer. Pathol Oncol Res 2015 Sep; 21(4): 941-6. (IF: 1.940; Pathology 36/79; Oncology 157/213)

  35. Lin LY, Yeh YC, Chu CH, Won JGS, Shyr YM, Chao Y, Li CP, Wang SE, Chen MH*.  Endocan Expression is Correlated with Poor Progression-Free Survival in Patients with Pancreatic Neuroendocrine Tumors. Medicine (Baltimore) 2017 Oct; 96(41): e8262. (IF: 1.803; Medicine, General & Internal 58/154)

  36. Tsai SH, Liu CA, Huang KH, Lan YT, Chen MH, Chao Y, Lo SS, Li AF, Wu CW, Chiou SH, Yang MH, Shyr YM, Fang WL*.  Advances in Laparoscopic and Robotic Gastrectomy for Gastric Cancer. Pathol Oncol Res 2017 Jan; 23(1): 13-7. Epub 2016 Oct. (IF: 1.736; Pathology 46/79; Oncology 169/217)

  37. Chang ME, Lei HJ*, Chen MH, Yeh YC, Li CP, Hung YP, Hsia CY, Liu CA, Chau GY, Chao Y.  Evaluation of Prognostic Factors and Implication of Lymph Node Dissection in Intrahepatic Cholangiocarcinoma: 10-Year Experience at a Tertiary Referral Center. J Chin Med Assoc 2017 Mar; 80(3): 140-6. Epub 2017 Feb. (IF: 1.252; Medicine, General & Internal 82/154)

  38. Chiu HY, Lin LY, Chou WC, Fang WL, Shyr YM, Yeh YC, Mu-Hsin Chang P, Chen MH, Hung YP, Chao Y, Chien SH*, Chen MH.  Toxicities, Safeties and Clinical Response of Dacarbazine-Based Chemotherapy on Neuroendocrine Tumors in Taiwan Population. J Chin Med Assoc 2018 May; 81(5): 423-8. Epub 2017 Dec. (IF: 1.252; Medicine, General & Internal 82/154)

  39. Chen SC, Chen MH, Li CP, Chen MH, Chang PM, Liu CY, Tzeng CH, Liu YM, Yen SH, Chao Y, Huang PI.  External Beam Radiation Therapy with or without Concurrent Chemotherapy for Patients with Unresectable Locally Advanced Hilar Cholangiocarcinoma. Hepato-Gastroenterol 2015 Jan-Feb; 62(137): 102-7. (IF: 0.792; Surgery 155/200; Gastroenterology & Hepatology 72/79)

 

電話:(02) 2875-7270
傳真:(02) 2874-9425
e-mail:d-ctc@vghtpe.gov.tw

11217
臺北市北投區石牌路二段201號
交通資訊
維護單位:腫瘤醫學部

目前在線人數: 5  |   今日瀏覽人次: 260  |   總瀏覽人次: 316300  |   本院為無菸醫院  |   我的E政府  |   無障礙標章 A+